Home World News Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with... World News Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 806 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO... September 20, 2021 CancerLand Bookshelf : Loosen July 26, 2021 EMA Recommends Granting a Marketing Authorisation for Senaparib October 15, 2026 Veteran and His Loyal Dog Pass Away Within Hours Of Each... May 21, 2020 Load more HOT NEWS 15% of People With Lung Cancer Have an Inherited Mutation for... EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan Study Finds the Cost of Treating Metastatic Breast Cancer Could More... FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic...
